Company intelligence / Profile preview

Yantai Heyuan Aidis Biomedical Technology

Yantai, Shandong Sheng, Chinacorporate.target.com ↗

Ownership: Private
Development stage: Other

Overview

Oba01, the lead program, is an antibody-drug conjugate targeting DR5 x Tubulin. It is in Phase 1 clinical trials for locally advanced/metastatic non-small cell lung cancer to evaluate safety, tolerability, and determine recommended dose for further studies. There are also preclinical programs targeting pancreatic cancer and neoplasms.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate (ADC)
Industry: Biotech

Drug pipeline

1 asset

Oba01

Beyond the preview

Go deeper on Yantai Heyuan Aidis Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yantai Heyuan Aidis Biomedical Technology.

Explore the full profile